Peter Blume-Jensen, Acrivon Therapeutics CEO
June 29, 2021 08:00 AM EDTUpdated 10:31 AM
Startups
Deals

Can a small band of bio­phar­ma play­ers suc­ceed where Eli Lil­ly failed? They’re tak­ing a shot

John Carroll

Editor & Founder

Eli Lil­ly didn’t try to spin any­thing about the mid-stage da­ta they got on their CHK1/CHK2 drug prex­as­ert­ib for ovar­i­an can­cer pa­tients. The drug failed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

A service from the Financial Times